The “Centre Hospitalier de la Côte Basque” in France Has Started the Evaluation of the Biolog-id’s C-LOG® Solution
The Centre Hospitalier de la Côte Basque (CHCB) in Bayonne has been using Biolog-id's C-LOG® solution since early April 2019. This solution secures and optimizes the circuit of chemotherapy and immunotherapy, from their preparation all the way to the administration to the patient.
The C-LOG® solution has been used at the CHCB. "During the last HAS audit, a lack of traceability was revealed in the chemotherapy circuit. In order to close this gap, we decided to install the C-LOG® solution which, in addition to securing the administration to the patient's bed, makes it possible to trace the preparation circuit from the pharmacy to the reception in the nurses station, " says Dr. Burtin, Pharmacist at CHCB. The solution will be tested for evaluation for 3 months before final adoption.
"The RFID (Radio Frequency Identification) technology is the foundation of our solution. The tag affixed on each preparation contains the product and patient data. This information is updated in real-time and can be consulted throughout the circuit," says Alexandre Guémard, Pharmacist, Product Manager, Biolog-id.
"The automation of information exchanges will facilitate daily actions: inventory management, traceability of returns, transport monitoring," says Dr. Christophe Burtin.
"By ensuring traceability and real-time access to information for healthcare professionals, C-LOG® enhances patient safety, reduces operational costs and improves working conditions," concludes Pierre Parent, President of Biolog-id.
The Centre Hospitalier de la Côte Basque (CHCB) is a Centre Hospital on 3 main sites. Supporting establishment of GHT Navarre-Basque Coast, it gathers more than 300 doctors and 3000 professionals in more than 60 services representing 40 specialties.
Biolog-id has developed a patented smart solution for the management and traceability of sensitive health products, based on RFID technology: blood products, plasma for fractionation and chemotherapy. Biolog-id operates in North America, Europe, Middle East, India and Asia Pacific region and has 90 employees worldwide. Biolod-id is owned by its founder, managers and the Xerys Funds.www.biolog-id.com
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-GA-ASI11.11.2019 18:02:05 CET | Press release
GA-ASI to Conduct Series of Capability Demonstrations in Europe
AL-ZMC11.11.2019 18:02:05 CET | Press release
ZMC Partners With CommentSold
FINEOS-CORPORATION11.11.2019 15:22:09 CET | Press release
Novarica Market Navigator Report Validates FINEOS is the Market Leader in Life, Accident and Health Claims Systems in North America By Client Base
CA-PULMONX11.11.2019 14:32:06 CET | Press release
The New 2020 Report from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Gives Highest Evidence Rating to Endobronchial Valves, including the Zephyr Valve, for Treatment of Emphysema / COPD
JANSSEN11.11.2019 14:28:06 CET | Press release
TREMFYA®▼ (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, Meets Primary Endpoints of Superior ACR20 Responses versus Placebo at Week 24 in Phase 3 Psoriatic Arthritis Studies
NJ-WIPRO-LIMITED11.11.2019 13:57:05 CET | Press release
Wipro Implements SAP S/4HANA® for Sydney Water
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom